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Cardiovascular	  disease	  is	  the	  leading	  cause	  of	  death	  in	  the	  United	  States.	  	  
Atherosclerosis	  is	  the	  main	  contributing	  factor	  for	  CVD.	  Current	  treatment	  methods	  
for	  atherosclerosis	  include	  balloon	  angioplasty	  and	  stent	  implantation,	  which	  both	  
have	  drawbacks	  associated	  with	  them.	  Balloon	  angioplasty	  shows	  restenosis	  in	  3-­‐6	  
months	  after	  deployment	  in	  25-­‐50%	  of	  patients.	  Bare	  metal	  stents	  have	  all	  the	  risks	  
associated	  with	  implanting	  a	  medical	  device	  in	  a	  blood	  contacting	  area	  along	  with	  
restenosis	  due	  to	  neointimal	  hyperplasia	  and	  stent	  fracture.	  In	  coronary	  arteries,	  
drug-­‐eluting	  stents	  (DES)	  have	  been	  shown	  to	  be	  very	  safe	  and	  effective	  with	  a	  very	  
low	  percentage	  of	  major	  adverse	  cardiac	  events	  when	  implanted	  properly,	  but	  they	  
require	  double	  antiplatelet	  therapy	  for	  a	  minimum	  of	  1	  year	  and	  have	  proven	  less	  
effective	  in	  peripheral	  arteries.	  	  
In	  peripheral	  arteries	  stents	  have	  not	  been	  as	  effective	  because	  of	  the	  
increased	  stresses	  put	  on	  the	  arteries	  by	  muscle	  contractions	  and	  movement.	  Most	  
notably	  the	  superficial	  femoral	  artery	  (SFA)	  travels	  through	  the	  hunter’s	  or	  
adductor	  canal	  in	  the	  quadriceps.	  The	  stress	  from	  quadriceps	  contractions	  can	  lead	  
to	  stent	  fracture	  and	  ultimately	  dissection	  of	  the	  artery.	  To	  try	  and	  solve	  this	  
problem	  drug	  coated	  balloons	  have	  tried	  to	  combine	  the	  positive	  qualities	  of	  DES	  for	  
localized	  anti-­‐proliferative	  drug	  delivery	  with	  angioplasty	  balloons	  that	  do	  not	  leave	  
foreign	  materials	  in	  the	  body.	  Estrogen	  is	  one	  such	  anti-­‐proliferative	  drug	  that	  has	  
been	  shown	  to	  inhibit	  smooth	  muscle	  cell	  proliferation	  in	  vitro	  and	  in	  vivo.	  	  
To	  study	  the	  safety	  and	  efficacy	  of	  an	  estrogen-­‐coated	  balloon	  in	  vitro	  static	  
studies	  were	  performed.	  These	  studies	  used	  static	  weight	  simulations	  to	  
iii	  
approximate	  an	  estrogen-­‐coated	  balloon	  expansion.	  Cells	  were	  then	  analyzed	  to	  
examine	  the	  simulation’s	  effect	  on	  cell	  proliferation,	  apoptosis,	  hypertrophy,	  and	  
phenotype.	  The	  studies	  statistically	  supported	  that	  estrogen	  treated	  balloon	  
angioplasty	  simulation	  had	  lower	  cell	  proliferation	  than	  uncoated	  balloon	  
angioplasty	  simulation	  and	  the	  control.	  The	  estrogen	  treated	  balloon	  angioplasty	  
simulation	  also	  showed	  no	  statistical	  significant	  differences	  in	  the	  amount	  of	  
apoptosis,	  hypertrophy,	  or	  phenotypic	  change	  when	  compared	  to	  uncoated	  balloon	  
angioplasty	  simulation.	  
A	  dynamic	  vascular	  flow	  model	  was	  designed	  to	  replicate	  an	  interventional	  
cardiologist’s	  path	  from	  balloon	  insertion	  to	  deployment	  in	  the	  SFA.	  This	  model	  will	  
be	  used	  to	  analyze	  coating	  techniques	  and	  drug	  lost	  from	  the	  balloon	  surface	  while	  
the	  balloon	  is	  in	  transit	  to	  the	  site	  of	  deployment.	  The	  flow	  model	  has	  the	  ability	  to	  
be	  modified	  to	  simulate	  varying	  amounts	  of	  vessel	  stenosis.	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CHAPTER	  I	  
Introduction	  and	  Background:	  
1.1	  Atherosclerosis:	  
	   Coronary	  artery	  disease	  (CAD)	  is	  the	  most	  common	  form	  of	  heart	  disease	  in	  
the	  United	  States,	  affecting	  greater	  than	  16	  million	  people	  [1].	  	  CAD	  forms	  as	  a	  result	  
of	  atherosclerosis,	  where	  plaque	  forms	  in	  the	  arteries	  causing	  the	  artery	  to	  narrow.	  	  
Atherosclerosis	  is	  a	  disease	  that	  occurs	  over	  time	  with	  fibrofatty	  plaque	  growing	  in	  
the	  vascular	  lumens,	  obstructing	  blood	  flow,	  and	  weakening	  the	  underlying	  media	  
[2].	  	  Atherosclerosis	  can	  begin	  in	  the	  first	  decade	  of	  a	  patient’s	  life	  and	  is	  clinically	  
silent	  while	  it	  grows	  [2].	  	  Atherosclerosis	  is	  a	  chronic	  inflammatory	  response	  of	  the	  
arterial	  wall	  that	  is	  initiated	  when	  the	  endothelium	  is	  injured	  [2].	  	  The	  major	  
consequences	  of	  atherosclerosis	  are	  cerebral	  infarction,	  myocardial	  infarction,	  and	  
peripheral	  vascular	  disease	  [2].	  	  The	  plaque	  found	  in	  an	  atherosclerotic	  vessel	  
usually	  consists	  of	  a	  necrotic	  center	  that	  contains	  cholesterol	  crystals,	  foam	  cells,	  
cell	  debris,	  and	  calcium	  [2].	  	  The	  vascular	  media	  and	  a	  fibrous	  cap	  that	  protrudes	  
into	  the	  vessel	  lumen	  encapsulate	  the	  necrotic	  center.	  	  The	  fibrous	  cap	  consists	  of	  
macrophages,	  foam	  cells,	  collagen,	  vascular	  smooth	  muscle	  cells,	  and	  elastin	  among	  
other	  things	  [2].	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Figure	  1:	  Histologic	  photo	  of	  an	  atherosclerotic	  plaque	  where	  L	  represents	  the	  arterial	  lumen,	  F	  
represents	  the	  fibrous	  cap,	  and	  C	  represents	  the	  necrotic	  core	  [2].	  
	  
The	  environmental	  risk	  factors	  of	  atherosclerosis	  include	  hypertension,	  
hemodynamics,	  viruses,	  smoking,	  lipid	  rich	  diets,	  toxins,	  and	  immune	  reactions	  [2].	  
Genetics	  also	  plays	  a	  large	  role	  in	  the	  formation	  of	  stenotic	  vessels	  with	  high	  levels	  
of	  LDL,	  reduced	  levels	  of	  HDL,	  diabetes,	  and	  obesity	  all	  being	  risk	  factors	  mainly	  
attributed	  to	  a	  patient’s	  genes	  [2].	  Atherosclerosis	  can	  be	  reversible	  if	  the	  patient	  
begins	  a	  diet	  and	  exercise	  routine	  along	  with	  smoking	  cessation	  (if	  applicable)	  and	  
treatment	  for	  any	  diseases	  that	  increase	  the	  risk	  of	  atherosclerosis	  [2].	  
	   Atherosclerosis	  formation	  begins	  as	  a	  fatty	  streak,	  which	  consists	  
predominantly	  of	  lipid-­‐filled	  macrophages,	  vascular	  smooth	  muscle	  cells,	  and	  T-­‐
lymphocytes	  [3,4].	  Fatty	  streaks	  are	  thought	  to	  form	  by	  the	  retention	  of	  lipoproteins	  
in	  the	  endothelial	  and	  the	  lipoproteins	  undergoing	  modification	  (thought	  to	  be	  
caused	  by	  oxidation	  of	  the	  lipoprotein)	  once	  there	  [5].	  Monocytes	  then	  begin	  to	  
adhere	  to	  the	  endothelium	  where	  the	  modified	  lipoproteins	  are	  and	  via	  chemotaxis	  
signal	  more	  lymphocytes	  to	  the	  area.	  Once	  monocytes	  accumulate	  in	  the	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subendothelial	  space,	  they	  differentiate	  in	  to	  macrophages.	  The	  macrophages	  begin	  
to	  uptake	  excess	  lipids	  and	  form	  foam	  cells	  [5].	  	  
	   The	  accumulation	  of	  foam	  cells	  and	  other	  lymphocytes	  will	  continue	  to	  grow	  
over	  time	  and	  thus	  enter	  the	  tunica	  media	  of	  the	  vessel	  where	  vascular	  smooth	  
muscle	  cells	  (VSMCs)	  reside	  [5].	  This	  amount	  of	  vascular	  injury	  leads	  to	  VSMCs	  to	  
migrating	  out	  of	  the	  tunica	  media	  [6].	  The	  migration	  of	  VSMCs	  out	  of	  the	  tunica	  
media	  leads	  to	  fatty	  streaks	  becoming	  fibrofatty	  lesions	  [5].	  Once	  outside	  of	  their	  
normal	  location,	  VSMCs	  change	  from	  the	  contractile	  phenotype	  to	  the	  synthetic	  
phenotype.	  VSMCs	  in	  the	  synthetic	  phenotype	  begin	  to	  proliferate	  rapidly	  and	  lay	  
down	  a	  vast	  network	  of	  extracellular	  matrix	  [6].	  	  
1.2	  Estrogen:	  
	   It	  has	  been	  shown	  that	  premenopausal	  women	  have	  a	  lower	  rate	  of	  
atherosclerosis	  than	  men	  of	  the	  same	  age	  [5].	  There	  have	  been	  numerous	  human	  
and	  animal	  studies	  that	  have	  documented	  a	  statistically	  significant	  gender	  
difference	  in	  the	  occurrence	  of	  CVD	  [5].	  In	  the	  Framingham	  Study,	  Kannel	  and	  
collaborators	  [7]	  showed	  that	  below	  the	  age	  of	  60	  men	  develop	  CVD	  at	  two	  times	  
the	  rate	  of	  women	  [5].	  The	  same	  study	  also	  showed	  that	  postmenopausal	  women	  
have	  almost	  twice	  the	  incidence	  of	  CVD	  when	  compared	  to	  premenopausal	  women	  
[5].	  These	  findings	  lead	  to	  the	  proposal	  that	  estrogen	  plays	  a	  key	  role	  in	  preventing	  
atherosclerosis	  formation.	  	  
	   There	  have	  been	  studies	  that	  suggest	  that	  since	  the	  mortality	  rates	  for	  
women	  in	  their	  sixties	  or	  seventies	  are	  still	  significantly	  lower	  than	  that	  of	  men	  of	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the	  same	  age,	  that	  the	  hypothesis	  that	  estrogen	  protects	  women	  from	  CVD	  is	  false	  
[8].	  Since	  atherosclerosis	  is	  a	  slow	  progressing	  disease,	  it	  makes	  since	  that	  if	  
estrogen	  exhibited	  a	  protective	  effect	  against	  plaque	  formation	  a	  swift	  rise	  in	  CVD	  
rates	  would	  not	  be	  seen	  very	  soon	  after	  menopause	  [5].	  Also	  estrogen	  production	  in	  
the	  ovaries	  declines	  slowly	  over	  a	  15-­‐20	  year	  period	  [5].	  The	  fact	  that	  menopause	  is	  
judged	  to	  begin	  when	  menstruation	  ends	  [7],	  the	  classification	  of	  going	  from	  
premenopausal	  to	  postmenopausal	  does	  not	  take	  into	  account	  this	  gradual	  estrogen	  
decline.	  	  
	   The	  studies	  that	  claimed	  estrogen	  was	  not	  involved	  in	  the	  decreased	  CVD	  in	  
women	  are	  also	  refuted	  by	  the	  studies	  conducted	  with	  postmenopausal	  women	  and	  
animals	  receiving	  estrogen	  replacement	  therapy	  [5].	  Adams	  and	  collaborators	  
performed	  multiple	  studies	  documenting	  the	  protective	  effects	  of	  estrogen	  on	  
primates.	  In	  one	  study,	  primates	  were	  subjected	  to	  an	  ovariectomy	  and	  fed	  an	  
atherogenic	  diet,	  with	  half	  of	  the	  primates	  receiving	  estrogen	  treatments.	  The	  
primates	  that	  were	  not	  given	  the	  estrogen	  had	  twice	  as	  much	  atherosclerosis	  
formation	  when	  compared	  to	  the	  estrogen	  treated	  primates	  [9].	  In	  humans,	  
Stampfer	  and	  Colditz	  performed	  a	  meta-­‐analysis	  that	  estimated	  the	  relative	  risk	  for	  
patients	  receiving	  estrogen	  replacement	  therapy	  was	  0.56	  (95%	  confidence	  
interval)	  when	  compared	  with	  patients	  not	  receiving	  the	  treatment	  [10]	  
	   There	  have	  also	  been	  multiple	  in	  vivo	  animal	  studies	  on	  multiple	  different	  
species	  that	  demonstrate	  the	  formation	  of	  neointimal	  hyperplasia	  that	  occurs	  after	  
balloon	  expansion	  in	  the	  vessel	  is	  diminished	  in	  the	  presence	  of	  estrogen,	  while	  
without	  estrogen	  there	  is	  a	  marked	  increase	  [6].	  17	  β-­‐estradiol	  has	  been	  shown	  to	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have	  many	  favorable	  cardio-­‐protective	  attributes	  that	  include:	  inhibition	  of	  vascular	  
smooth	  muscle	  cells	  migration	  and	  proliferation,	  relaxation	  of	  the	  coronary	  vessels	  
through	  endothelial	  NO	  synthase	  activity,	  and	  reduction	  of	  monocyte	  and	  platelet	  
aggregation	  in	  the	  vessel	  [6].	  	  
	   The	  cardio-­‐protective	  effects	  of	  estrogen	  are	  induced	  by	  altering	  mitogen-­‐
activated	  protein	  kinase	  (MAPK)	  cascades	  [6].	  The	  specific	  pathways	  that	  estrogen	  
interferes	  with	  involve	  MAPK	  p38	  and	  p42/44	  [6].	  The	  p38	  MAPK	  pathways	  are	  
involved	  in	  the	  mitogenic	  and	  chemotactic	  processes	  carried	  out	  by	  an	  array	  of	  
different	  cell	  types	  [6].	  
	   It	  has	  also	  been	  shown	  that	  males	  carry	  the	  same	  estrogen	  receptor	  on	  their	  
vascular	  smooth	  muscle	  cells	  as	  females	  [11].	  While	  Espinosa	  et	  al	  showed	  there	  
was	  a	  decreased	  response	  to	  estrogen	  treatments	  in	  male	  rats,	  when	  compared	  to	  
females	  of	  the	  same	  age,	  they	  still	  showed	  that	  there	  was	  an	  anti-­‐proliferative	  effect	  
and,	  through	  western	  blot,	  proved	  the	  existence	  of	  the	  estrogen	  receptor	  in	  male	  
vascular	  smooth	  muscle	  cells	  [11].	  	  
1.3	  Balloon	  Angioplasty:	  
	   Dr.	  Charles	  Dotter	  performed	  the	  first	  balloon	  angioplasty	  in	  1964.	  	  He	  
invented	  the	  technique	  and	  procedure	  for	  an	  82-­‐year	  old	  patient	  with	  severe	  
peripheral	  vascular	  disease	  who	  refused	  amputation	  of	  her	  gangrenous	  leg	  [12].	  	  Dr.	  
Dotter	  used	  a	  guide	  wire	  and	  coaxial	  Teflon	  catheters	  to	  dilate	  the	  stenosis	  of	  the	  
superficial	  femoral	  artery	  [12].	  	  The	  artery	  stayed	  open	  for	  the	  remaining	  two	  and	  a	  
half	  years	  of	  the	  patient’s	  life	  [12].	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   It	  was	  not	  until	  1977	  that	  balloon	  angioplasty	  was	  used	  on	  a	  waking	  patient	  
(as	  is	  done	  today)	  in	  a	  coronary	  artery	  [12].	  	  Balloon	  angioplasty	  has	  drastically	  
improved	  from	  its	  early	  beginnings.	  	  Doctors	  used	  to	  perform	  the	  procedure	  without	  
the	  use	  of	  guide	  wires	  and	  the	  balloons	  had	  low	  burst	  pressures	  and	  were	  quite	  
large	  compared	  to	  today’s	  models	  [13].	  	  Because	  of	  the	  hindrances	  of	  early	  
angioplasty	  technology	  and	  the	  complicated	  geometry	  and	  nature	  of	  vessels	  
containing	  stenosis,	  only	  10%	  of	  the	  patient	  population	  was	  able	  to	  get	  this	  
procedure	  [13].	  	  	  
	   Balloon	  angioplasty	  is	  usually	  done	  today	  by	  inserting	  a	  deflated	  balloon	  on	  a	  
catheter	  into	  the	  femoral	  or	  radial	  artery	  on	  a	  guide	  wire	  and	  inflating	  the	  balloon	  
repeatedly	  in	  the	  area	  of	  stenosis.	  	  When	  the	  balloon	  inflates,	  it	  depresses	  the	  plaque	  
against	  the	  artery,	  which	  reopens	  the	  artery	  [1].	  
	  
	  
Figure	  2:	  Diagram	  showing	  a	  balloon	  angioplasty	  procedure	  [14].	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   Balloon	  angioplasty	  increases	  the	  flow	  through	  the	  formerly	  occluded	  artery,	  
but	  there	  is	  a	  restenosis	  rate	  of	  25-­‐50%	  within	  the	  first	  six	  months	  after	  the	  
procedure	  [13].	  
1.4	  Neointimal	  Hyperplasia:	  
	   Restenosis	  of	  vessels	  after	  balloon	  angioplasty	  normally	  occurs	  as	  the	  result	  
of	  neointimal	  hyperplasia.	  	  When	  the	  balloon	  is	  inflated	  the	  walls	  of	  the	  vessel	  
become	  damaged	  and	  neointimal	  hyperplasia	  is	  the	  injury	  and	  immune	  response	  to	  
the	  vascular	  injury.	  Growth	  factors,	  cytokines,	  metalloproteases,	  and	  upregulation	  of	  
genes,	  among	  other	  factors,	  cause	  smooth	  muscle	  cell	  proliferation,	  activation	  of	  
platelets	  and	  macrophages,	  remodeling	  of	  the	  extracellular	  matrix,	  and	  smooth	  
muscle	  cell	  migration	  into	  the	  vascular	  lumen	  [15].	  Once	  the	  vascular	  smooth	  
muscle	  cells	  have	  entered	  the	  artery	  lumen,	  they	  begin	  to	  change	  their	  phenotypes	  
from	  a	  contractile	  morphology	  to	  a	  synthetic	  one	  [15].	  	  Once	  in	  the	  synthetic	  
phenotype,	  vascular	  smooth	  muscle	  cells	  begin	  to	  proliferate	  and	  spread	  
extracellular	  matrix	  [15].	  	  The	  most	  effective	  manner	  or	  altering	  the	  postoperative	  
natural	  healing	  process	  is	  interfering	  with	  molecular	  cell	  division	  [15].	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Figure	  3:	  Diagram	  of	  neointimal	  hyperplasia	  progression	  [2].	  
1.5	  Peripheral	  Vascular	  Disease:	  
	   Peripheral	  vascular	  (arterial)	  disease	  (PVD	  or	  PAD)	  occurs	  when	  there	  is	  an	  
occlusion	  in	  a	  vessel	  that	  is	  not	  a	  coronary	  artery,	  in	  the	  brain,	  or	  the	  aortic	  arch	  
[16].	  While	  most	  peripheral	  occlusions	  occur	  in	  the	  lower	  extremities,	  there	  are	  also	  
many	  cases	  involving	  the	  renal	  arteries,	  among	  others.	  PVD	  patients	  normally	  
present	  with	  claudication	  (described	  as	  pain,	  numbness	  or	  soreness	  felt	  during	  or	  
after	  walking),	  which	  is	  a	  symptom	  of	  critical	  limb	  ischemia	  (CLI)	  [16].	  CLI	  in	  the	  
femoro-­‐popliteal	  area	  normally	  presents	  with	  long,	  diffuse	  lesions	  and	  occlusions	  
[16].	  If	  PVD	  is	  left	  untreated	  the	  usual	  outcome	  is	  necrosis	  of	  the	  downstream	  tissue	  
lead	  to	  the	  need	  for	  amputation	  [16].	  	  
1.6	  Drug-­‐Eluting	  Stents:	  
	   When	  drug-­‐eluting	  stents	  (DES)	  were	  first	  explored,	  the	  main	  concern	  was	  
lowering	  the	  rate	  of	  stent	  thrombosis	  in	  bare	  metal	  stents,	  which	  were	  at	  high	  rates	  
of	  20-­‐25%	  [15].	  To	  combat	  these	  rates	  anticoagulant	  coated	  stents	  were	  developed.	  	  
Heparin-­‐coated	  stents	  represent	  the	  first	  step	  to	  loading	  medication	  on	  to	  stents	  
[15].	  	  These	  stents	  failed	  however,	  as	  they	  were	  developed	  at	  the	  same	  time	  as	  
improvements	  to	  stenting	  techniques	  and	  stenting	  technology,	  as	  well	  as	  the	  
introduction	  of	  effective	  antiplatelet	  drugs.	  These	  advancements	  in	  stent	  placement	  
technology	  and	  drug	  therapy	  yielded	  the	  same	  stent	  thrombus	  rate	  improvement	  at	  
a	  lower	  price	  	  [17].	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   Stopping	  cell	  division	  required	  the	  use	  an	  anti-­‐proliferative	  drug,	  but	  there	  
was	  the	  challenge	  of	  having	  the	  drug	  remain	  localized	  in	  a	  dynamic	  environment.	  	  
The	  body’s	  blood	  flows	  in	  a	  closed	  loop	  throughout	  the	  body	  at	  a	  high	  rate	  of	  speed,	  
so	  getting	  the	  drug	  to	  stay	  in	  the	  small	  area	  of	  blood	  vessel	  desired	  could	  not	  be	  
achieved	  by	  current	  delivery	  methods.	  	  The	  previous	  work	  on	  heparin-­‐coated	  stents	  
provided	  the	  answer	  to	  this	  problem,	  but	  to	  make	  this	  technique	  work	  there	  were	  
many	  potential	  pitfalls	  (Table	  1)	  that	  had	  to	  be	  avoided	  [15].	  
	  
Pitfalls	   Variables	  
Bio	  and	  blood	  compatibility	   Physiochemical	  properties	  of	  polymer	  and	  drug	  	  
Limited	  surface	  area	   Drug	  potency;	  total	  amount	  of	  drug	  
Maintain	  drug	  properties	  after	  coating	   Degree	  of	  cross-­‐linking	  
Heterogeneous	  underlying	  tissue	  characteristics	   Drug	  solubility	  
Sterilization	  and	  stent	  expansion	   Polymer	  and	  drug	  elasticity	  
Inflammation	  
Porosity	  of	  the	  polymer,	  molecular	  weight	  of	  the	  
polymer,	  thickness	  of	  the	  coating,	  degree	  and	  
mode	  of	  degradation;	  drug	  toxicity;	  local	  drug	  
concentration	  (per	  mm2);	  drug	  solubility	  
	  
Table	  1:	  Table	  describing	  the	  pitfalls	  and	  variables	  associated	  with	  drug-­‐eluting	  stents	  [15].	  
	  
	   The	  two	  main	  drugs	  used	  in	  drug	  eluting	  stents	  are	  Sirolimus	  (also	  known	  as	  
rapamycin)	  and	  Paclitaxel.	  Sirolimus	  is	  a	  macrolide	  antibiotic	  that	  has	  anti-­‐
inflammatory,	  immunosuppressive,	  and	  anti-­‐proliferative	  properties	  that	  make	  it	  
very	  useful	  in	  preventing	  neointimal	  hyperplasia	  by	  inhibiting	  the	  proliferative	  and	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migratory	  response	  of	  smooth	  muscle	  cells	  at	  the	  site	  of	  stent	  deployment	  [18].	  	  The	  
drug	  inhibits	  the	  transition	  from	  the	  G1	  phase	  to	  the	  S	  phase	  in	  the	  cell	  cycle,	  thus	  
blocking	  proliferation	  without	  inducing	  cell	  death	  [18].	  Paclitaxel	  is	  a	  mitotic	  
inhibitor	  that	  stops	  proliferation	  by	  stabilizing	  cell’s	  microtubules	  [18].	  This	  
stabilizing	  of	  the	  microtubules	  does	  not	  allow	  them	  to	  breakdown,	  which	  is	  
necessary	  for	  cell	  division	  [18].	  
	   While	  drug-­‐eluting	  stents	  have	  greatly	  improved	  atherosclerosis	  treatment,	  
there	  are	  still	  areas	  where	  they	  are	  not	  as	  useful	  and	  in	  some	  cases	  dangerous.	  In	  
peripheral	  areas	  where	  high	  stresses	  are	  put	  on	  the	  arteries,	  and	  thus	  also	  any	  
stents	  implanted	  in	  these	  areas,	  there	  is	  a	  risk	  of	  stent	  fracture	  [19].	  	  The	  superficial	  
femoral	  artery	  (SFA)	  travels	  through	  the	  Hunter’s	  (aka	  Adductor)	  canal.	  This	  runs	  
through	  the	  quadriceps	  and	  experiences	  high	  loading	  and	  movement	  during	  normal	  
daily	  activities	  [19].	  There	  are	  many	  reported	  cases	  of	  stent	  fractures	  in	  this	  area	  
[19].	  When	  the	  stent	  fractures	  it	  can	  lead	  to	  either	  to	  occlusion	  of	  the	  stented	  site,	  or,	  
in	  severe	  cases,	  the	  stent	  wires	  can	  pierce	  the	  vessel	  wall	  and	  lead	  to	  dissection	  of	  
the	  artery	  [19].	  
1.7	  Drug-­‐Coated	  Balloons:	  
	   The	  shortfalls	  of	  stenting	  (with	  drug-­‐eluting	  or	  bare	  metals	  stents)	  have	  lead	  
to	  resurgence	  in	  research	  on	  drug-­‐coated	  balloons	  (DCB)	  [20].	  Using	  drug-­‐coated	  
balloons,	  the	  physician	  can	  maintain	  the	  anti-­‐proliferative	  effects	  of	  drug-­‐eluting	  
stents	  without	  the	  limitations	  associated	  with	  leaving	  a	  stent	  in	  the	  vasculature.	  
Drug-­‐coated	  balloons	  can	  be	  used	  to	  treat	  areas	  where	  DES	  do	  not	  perform	  well,	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such	  as,	  small	  vessels,	  where	  scaffolding	  obstructs	  major	  side	  branches,	  bifurcated	  
lesions,	  or	  long	  diffuse	  calcified	  lesions	  [20].	  Another	  advantage	  over	  DES	  is	  not	  
leaving	  polymer	  implants	  that	  have	  the	  possibility	  of	  causing	  chronic	  inflammation	  
and	  late	  thrombosis	  [21].	  DCB	  can	  also	  be	  used	  concurrently	  with	  stents.	  DCB	  have	  
the	  potential	  to	  repair	  in	  stent	  restenosis	  (ISR)	  that	  is	  seen	  in	  bare	  metal	  stents	  and	  
some	  DES,	  as	  well	  as	  can	  be	  used	  for	  drug	  delivery	  while	  expanding	  a	  bare	  metal	  
stent	  [20].	  	  
	   There	  are	  also	  additional	  potential	  advantages	  to	  DCB	  when	  compared	  to	  
DES	  (Table	  2)	  including	  eliminating	  the	  need	  for	  sustained	  double	  anti-­‐platelet	  
therapy,	  drug	  transfer	  to	  the	  entire	  vessel	  wall	  instead	  of	  just	  around	  stent	  struts,	  
rapid	  release	  of	  high	  concentrations	  of	  drug,	  and	  no	  stent	  left	  in	  the	  vessel	  that	  can	  
alter	  blood	  flow	  patterns	  [20].	  The	  one	  challenge	  that	  DCB	  cannot	  overcome	  is	  the	  
acute	  vessel	  recoil	  that	  occurs	  after	  balloon	  deployment	  because	  there	  is	  no	  stent	  
framework	  to	  hold	  the	  vessel	  fully	  open	  [20].	  	  
	  
	   Drug-­‐Eluting	  Stents	   Drug	  Coated	  Balloons	  
Platform	  of	  Delivery	   Stent	  scaffolding	   Balloon	  
Retention	   Polymer	  based	   Embedded/Imprinted	  
Drug	  Dose	   Low:	  <100	  to	  200μg	   High:	  300	  to	  600μg	  









Less	  drug	  spillage	  into	  
circulation	  
Proven	  efficacy	  in	  many	  
Leave	  no	  implant	  
Larger	  surface	  area	  
Less	  drug	  localization	  in	  
the	  vessel	  wall	  
Accessible	  to	  complex	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indications	  
No	  acute	  recoil	  tackled	  
dissection	  
lesions	  and	  long	  segments	  
May	  not	  require	  
prolonged	  DAPT	  
Table	  2:	  Comparison	  of	  Drug-­‐Eluting	  Stents	  and	  Drug	  Coated	  Balloons	  [Adapted	  from	  20].	  
For	  a	  drug-­‐coated	  balloon	  to	  be	  effective,	  there	  are	  many	  biological	  and	  technical	  considerations	  that	  
must	  be	  met	  (Table	  3).	  	  
	  
Drug	  Features	   Coating	  Features	   Delivery	  Features	   Catheter	  Features	  
Chemical	  structure	  





Optimal	  vessel	  wall	  
contact	  on	  delivery	  
Sustained	  
biological	  effect	  at	  




























of	  the	  coating	  on	  
vessel	  contact	  
	  
Table	  3:	  Considerations	  to	  make	  a	  DCB	  successful	  [Adapted	  from	  22].	  
	  
	   The	  delivery	  system	  used	  for	  DCB	  is	  very	  important	  to	  their	  actual	  efficacy	  at	  
treating	  atherosclerotic	  vessels.	  If	  the	  drug	  and	  balloon	  meet	  all	  the	  consideration	  in	  
Table	  3,	  a	  poor	  catheter	  delivery	  design	  will	  ruin	  the	  balloon.	  The	  balloons	  have	  to	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be	  able	  to	  keep	  the	  drug	  attached	  to	  it	  during	  transport	  and	  then	  rapidly	  release	  the	  
drug	  upon	  deployment	  [22].	  Current	  technologies	  have	  followed	  two	  main	  
strategies	  to	  ensure	  there	  are	  enough	  drug	  particles	  remaining	  on	  the	  balloon	  to	  
achieve	  the	  anti-­‐proliferative	  effects	  desired	  [17].	  The	  two	  techniques	  are	  to	  either	  
place	  a	  sheath	  around	  the	  balloon	  that	  is	  slid	  back	  once	  the	  deployment	  site	  is	  
reached,	  and	  the	  other	  is	  to	  load	  a	  higher	  concentration	  of	  drug	  than	  required	  with	  
the	  expectation	  of	  drug	  being	  lost	  in	  transit	  [17].	  	  
1.8	  Research	  Aims:	  
This	  study	  was	  aimed	  at	  testing	  the	  efficacy	  of	  estrogen	  treatment	  on	  vascular	  
smooth	  muscle	  cells	  in	  balloon	  angioplasty	  conditions.	  The	  three	  objectives	  for	  this	  
project	  were	  to	  (1)	  analyze	  the	  antiproliferative	  effects	  of	  estrogen	  on	  VSMCs,	  (2)	  
examine	  the	  reaction	  of	  VSMCs	  to	  a	  simulation	  of	  an	  estrogen	  treated	  balloon	  
expansion,	  and	  (3)	  design	  a	  dynamic	  vascular	  flow	  model	  to	  test	  drug	  retention	  on	  a	  
balloon	  in	  transit	  to	  deployment	  site.	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CHAPTER	  II	  
Materials	  &	  Methods:	  
2.1	  Cell	  Characterization:	  
	   	   Vascular	  smooth	  muscle	  cells	  were	  isolated	  from	  the	  aorta	  of	  a	  6-­‐8	  
week	  old	  female	  Sprague-­‐Dawley	  rat.	  All	  experiments	  were	  conducted	  on	  VSMCs	  
between	  passage	  3	  and	  passage	  6	  before	  use	  [23].	  
The	  cells	  were	  characterized	  to	  confirm	  that	  they	  were	  VSMCs.	  Western	  Blot	  was	  
used	  to	  confirm	  the	  phenotype	  of	  VSMCs	  through	  characterization	  of	  myosin	  heavy	  
chain	  and	  α-­‐actin.	  The	  cells	  were	  also	  immunostained	  with	  Phalloidin	  to	  confirm	  the	  
presence	  of	  α-­‐actin	  and	  the	  myosin	  heavy	  chain	  was	  tagged	  with	  GFP	  [24].	  	  
2.2	  Estrogen	  Studies:	  
	   VSMCs	  were	  seeded	  in	  a	  collagen-­‐coated	  24-­‐well	  plate	  with	  2*104	  VSMCs	  per	  
well.	  After	  24	  hours	  in	  Dulbecco’s	  modified	  Eagle	  medium	  (DMEM)	  (Gibco,	  Life	  
technologies,	  CA	  ,USA)	  with	  10%	  fetal	  bovine	  serum	  (FBS)	  (Corning	  Inc	  ,NY)	  1%	  
antibiotic-­‐antimicrobial	  (Ab-­‐Am)	  (Corning	  Inc,	  NY,	  USA)	  solution,	  without	  phenol	  
red,	  the	  VSMCs	  were	  rinsed	  with	  1x	  sterile	  Dulbecco’s	  phosphate	  buffer	  solution	  
(DPBS)	  (Corning	  Inc,	  NY,	  USA)	  and	  then	  growth	  arrested	  in	  DMEM	  solution	  with	  no	  
FBS	  for	  48	  hours.	  VSMCs	  were	  then	  rinsed	  in	  1x	  DPBS	  and	  then	  placed	  in	  fresh	  
DMEM	  with	  no	  FBS.	  VSMCs	  were	  then	  treated	  with	  20	  μM	  17-­‐β	  estradiol	  (Sigma	  
Aldrich,	  MO,	  USA)	  for	  5	  (n=4),	  15	  (n=4),	  and	  30	  (n=4)	  minutes,	  with	  solvent	  controls	  
containing	  an	  equal	  amount	  of	  dimethyl	  sulfoxide	  (DMSO)	  (Thermo	  Fisher,	  MA,	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USA)	  as	  the	  treatment	  group	  (n=4),	  and	  with	  DMEM	  solution	  with	  no	  FBS	  control	  
(n=4).	  After	  treatment	  the	  wells	  were	  rinsed	  with	  1x	  DPBS	  and	  then	  placed	  in	  
DMEM	  solution	  with	  1%	  FBS.	  VSMC	  proliferation	  was	  analyzed	  using	  methylthiazol	  
tetrazolium	  (MTT)	  (Sigma	  Aldrich,	  MO,	  USA)	  assay	  after	  24	  hours.	  
2.3	  MTT	  Assay:	  
	   3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐diphenyltetrazolium	  bromide	  was	  dissolved	  
in	  1x	  DPBS	  at	  a	  concentration	  of	  2mg/mL.	  VSMCs	  were	  rinsed	  with	  1x	  DPBS	  and	  
then	  placed	  in	  1ml	  of	  DMEM	  solution	  with	  no	  FBS.	  240μl	  of	  MTT	  was	  added	  to	  the	  
wells	  and	  the	  solution	  incubated	  for	  4	  hours.	  After	  incubation,	  the	  MTT-­‐DMEM	  
solution	  was	  removed	  and	  1mL	  of	  DMSO	  was	  added	  to	  the	  wells.	  Using	  a	  plate	  
reader,	  the	  absorbance	  was	  then	  read	  at	  570nm.	  
2.4	  Static	  Contact	  Study:	  
	   For	  static	  studies,	  0.15-­‐inch	  thick	  silicone	  sheeting	  (Specialty	  manufacturing	  
Inc,	  MI,	  USA)	  were	  sonicated	  in	  deionized	  water	  for	  30	  minutes	  and	  then	  autoclaved.	  
The	  silicone	  sheeting	  was	  then	  placed	  at	  the	  bottom	  of	  each	  well	  in	  a	  12-­‐well	  plate.	  
The	  sheets	  were	  then	  coated	  in	  with	  a	  1.5ml	  of	  100μg/ml	  collagen	  type	  1	  (Purecol®	  
3mg/ml,	  Advanced	  Biomatrix,	  CA,	  USA)	  solution	  for	  at	  least	  48	  hours	  in	  a	  37°C	  
incubator.	  The	  sheets	  were	  then	  rinsed	  with	  1x	  DPBS	  and	  wells	  were	  filled	  with	  
DMEM	  with	  10%	  FBS	  and	  then	  seeded	  the	  wells	  with	  2*105	  VSMCs	  per	  well.	  After	  24	  
hours,	  the	  wells	  were	  rinsed	  in	  1x	  DPBS.	  Six	  of	  the	  seeded	  sheets	  were	  placed	  in	  
DMEM	  with	  5%	  FBS	  while	  three	  wells	  placed	  in	  a	  20.25%	  Iopromide	  370	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(Ultravist®-­‐370mgI/ml,	  Bayer	  Medical,	  Germany)	  solution	  with	  40μM	  17-­‐β	  estradiol	  
in	  DMEM	  with	  5%	  FBS	  and	  	  dissolved	  in	  deionized	  water.	  Iopromide	  is	  used	  as	  an	  
effective	  solvent	  for	  lipophilic	  drug	  dissolution,	  allows	  for	  easier	  coating	  of	  the	  
balloon,	  and	  promotes	  smooth	  muscle	  cell	  inhibition	  [22].	  The	  Iopromide	  
concentration	  used	  came	  from	  previous	  studies	  done	  by	  another	  lab	  member	  that	  
has	  yet	  to	  be	  published.	  A	  polycarbonate	  indenter	  was	  then	  used	  as	  a	  platform	  to	  
apply	  weight	  to	  the	  cells	  for	  mimicking	  the	  pressure	  VSMCs	  feel	  during	  balloon	  
angioplasty	  inflation	  (Figure	  4).	  Polyethylene	  Terephthalate	  (PET)	  sheet	  was	  placed	  
on	  the	  end	  of	  the	  indenter	  to	  represent	  the	  material	  of	  the	  balloon.	  An	  indenter	  
loaded	  with	  a	  500g	  (4.9N)	  weight	  was	  placed	  in	  each	  of	  three	  wells	  for	  one	  minute.	  
The	  remaining	  three	  wells	  had	  an	  indenter	  with	  a	  PET	  sheet	  only	  without	  500g)	  
placed	  on	  the	  cells	  for	  one	  minute.	  All	  the	  experiments	  were	  repeated	  at	  least	  3	  
times	  for	  24	  and	  72	  hour	  results	  that	  were	  examined	  by	  MTT	  assay,	  Tunel	  apoptosis	  
assay	  (Promega)	  and	  hypertrophy	  studies.	  For	  the	  72	  hour	  studies	  all	  of	  the	  wells	  
were	  rinsed	  with	  1x	  DPBS	  and	  then	  filled	  with	  DMEM	  with	  5%	  FBS	  after	  24	  hours.	  	  
	  
Figure	  4:	  On	  left:	  SolidWorks	  representation	  of	  polycarbonate	  indenter.	  On	  right:	  SolidWorks	  
representation	  of	  indenter	  on	  VSMC	  seeded	  silicone	  sheet	  in	  a	  12-­‐well	  plate.	  The	  indenter	  consists	  of	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a	  cylinder	  piece	  (diameter	  20mm	  and	  height	  30mm)	  and	  a	  disc	  piece	  (10	  mm	  thick	  with	  50mm	  
diameter	  and	  20.5mm	  diameter	  slot	  for	  cylinder	  piece	  to	  fit	  in	  that	  is	  5mm	  deep)	  
	  
	  
For	  the	  static	  weight	  study	  we	  used	  a	  simulation	  performed	  by	  Rogers	  and	  
collaborators	  detailing	  the	  forces	  that	  VSMCs	  are	  subjected	  to	  during	  balloon	  
angioplasty	  [25].	  Using	  a	  2-­‐dimensional	  finite	  element	  analysis	  (FEA),	  they	  took	  a	  
cross	  section	  of	  an	  artery	  and	  showed	  the	  forces	  that	  a	  balloon	  places	  on	  a	  vessel	  
when	  it	  is	  inflated	  at	  8atm	  pressure.	  The	  FEA	  analysis	  showed	  that	  VSMCs	  
experience	  between	  0.004	  and	  0.04	  N/mm2	  depending	  on	  their	  position	  relative	  
balloon	  (as	  shown	  in	  Figure	  16)	  [25].	  Using	  these	  values	  we	  calculated	  that	  to	  
simulate	  this	  pressure	  on	  VSMCs	  in	  a	  well	  plate	  (well	  bottom	  area	  of	  3.83	  cm2)	  we	  
would	  need	  to	  put	  156	  to	  1560g	  of	  weight	  on	  the	  cells.	  We	  used	  500g	  (plus	  the	  
32.78g	  weight	  of	  the	  two	  indenter	  pieces	  combined)	  as	  our	  weight	  to	  closely	  
simulate	  the	  average	  forces	  that	  would	  be	  experienced	  when	  a	  balloon	  is	  inflated	  at	  
8atm.	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Figure	  5:	  2D	  FEA	  of	  a	  cross	  section	  of	  a	  balloon	  expanding	  into	  the	  vascular	  wall	  [25].	  
	  
2.5	  Tunel	  Apoptosis	  Assay:	  
	   VSMCs	  were	  rinsed	  in	  1x	  DPBS	  and	  then	  fixed	  in	  4%	  formaldehyde	  solution	  
(Sigma	  Aldrich	  MO,	  USA)	  for	  20	  minutes.	  VSMCs	  were	  rinsed	  with	  1x	  DPBS	  for	  5	  
minutes.	  	  VSMCs	  were	  permeabilized	  in	  a	  0.2%	  Triton	  X-­‐100	  (Thermofisher,	  MA,	  
USA)	  solution	  in	  DPBS	  for	  5	  minutes.	  VSMCs	  were	  rinsed	  with	  1x	  DPBS	  for	  5	  
minutes.	  VSMCs	  were	  then	  equilibrated	  in	  100μl	  of	  Equilibration	  Buffer	  for	  5	  
minutes.	  The	  Equilibration	  Buffer	  was	  removed	  and	  50μl	  of	  Terminal	  
Deoxynucleotidyl	  Transferase,	  Recombinant,	  enzyme	  (rTdT)	  incubation	  buffer	  was	  
added.	  The	  rTdT	  incubation	  buffer	  consisted	  of	  45μl	  of	  Equilibration	  Buffer,	  5μl	  of	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Nucleotide	  Mix,	  and	  1μL	  of	  rTdT	  Enzyme.	  VSMCs	  were	  then	  covered	  in	  aluminum	  
foil	  and	  incubated	  at	  37°C	  for	  60	  minutes.	  20X	  saline	  sodium	  citrate	  (SSC)	  was	  
diluted	  in	  deionized	  water	  to	  1X	  SSC	  and	  the	  cells	  were	  immersed	  in	  the	  solution	  for	  
15	  minutes	  to	  terminate	  the	  reaction.	  VSMCs	  were	  rinsed	  with	  1x	  DPBS	  three	  times	  
for	  5	  minutes	  each.	  All	  the	  cells	  were	  then	  stained	  with	  DAPI.	  The	  silicone	  sheets	  
were	  then	  mounted	  onto	  slides	  using	  Vectashield	  (Vector	  laboratories	  CA,	  USA)	  	  and	  
the	  edges	  were	  sealed	  and	  examined	  using	  a	  fluorescence	  microscope.	  Four	  pictures	  
were	  taken	  for	  each	  sample	  and	  a	  ratio	  between	  apoptotic	  cells	  and	  all	  cells	  were	  
analyzed	  using	  ImageJ	  (NIH).	  The	  ratio	  was	  compared	  between	  treatment	  and	  
control	  group	  for	  24	  and	  72-­‐hour	  studies.	  
2.6	  Cell	  Hypertrophy:	  
	   VSMCs	  were	  rinsed	  in	  1x	  DPBS	  and	  then	  fixed	  in	  4%	  formaldehyde	  for	  20	  
minutes.	  VSMCs	  were	  rinsed	  with	  1x	  DPBS	  for	  5	  minutes.	  Then	  the	  cells	  were	  
permeabilized	  in	  0.2%	  Triton	  X-­‐100	  solution	  in	  PBS	  for	  5	  minutes.	  VSMCs	  were	  
rinsed	  with	  1x	  DPBS	  for	  5	  minutes.	  The	  cells	  were	  then	  stained	  with	  25μg/ml	  
Phalloidin	  (500ug/ml.	  Sigma	  Aldrich,	  MO,	  USA)	  and	  nuclei	  were	  stained	  with	  DAPI.	  
The	  silicone	  sheets	  were	  then	  mounted	  onto	  slides	  using	  Vectashield,	  edges	  were	  
sealed	  and	  examined	  using	  a	  fluorescence	  microscope.	  Four	  pictures	  were	  taken	  for	  
each	  sample	  and	  the	  cells	  were	  measured	  using	  ImageJ	  for	  area	  and	  length	  of	  major	  
and	  minor	  axes.	  These	  were	  then	  compared	  between	  treatment	  and	  control	  for	  24	  
and	  72-­‐hour	  studies.	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2.7	  Drug	  Coating	  Study:	  
	   Sheets	  of	  PET	  were	  coated	  with	  three	  different	  solutions	  and	  examined	  under	  
fluorescence	  microscopy.	  The	  first	  coating	  was	  made	  by	  dissolving	  a	  10mg/ml	  17-­‐β	  
estradiol-­‐	  10%	  Iopromide	  mixture	  in	  100%	  ethanol	  as	  a	  solvent.	  The	  Iopromide	  
concentration	  used	  came	  from	  previous	  studies	  done	  by	  another	  lab	  member	  that	  
has	  yet	  to	  be	  published.	  The	  solution	  was	  then	  pipetted	  onto	  the	  PET	  and	  allowed	  to	  
dissolve.	  This	  same	  procedure	  was	  repeated	  with	  acetone	  as	  the	  solvent	  and	  also	  
with	  10mg/ml	  estrogen	  dissolved	  in	  100%	  ethanol.	  The	  coated	  PET	  sheets	  were	  
examined	  using	  fluorescence	  microscopy	  of	  the	  autofluorescent	  estrogen	  to	  
determine	  which	  coating	  left	  the	  most	  homogenous	  distribution	  of	  drug	  on	  the	  PET.	  
2.8	  Statistical	  Analysis:	  
	   For	  statistical	  analysis	  student’s	  two-­‐tailed	  T-­‐test	  was	  performed	  using	  
GraphPad	  Prism	  (GraphPad	  Software	  Inc,	  CA,	  USA)	  with	  p<0.05	  indicating	  statistical	  
significance.	   	  




	   Once	  the	  cells	  were	  isolated	  from	  the	  rat	  aorta	  they	  were	  characterized	  to	  
determine	  if	  they	  were	  VSMCs	  by	  Western	  Blot	  and	  Immunostaining	  Myosin	  Heavy	  
Chain	  (Figure	  5)	  and	  α-­‐actin	  (Figure	  6)	  	  
	  
	  
Figure	  6:	  Expression	  of	  Myosin	  Heavy	  Chain	  in	  smooth	  muscle	  cells	  shown	  by	  Western	  Blot	  and	  





Figure	  7:	  Expression	  of	  α-­‐actin	  in	  smooth	  muscle	  cells	  shown	  by	  Western	  Blot	  and	  Immunostaining	  
(length	  of	  scale	  bar	  is	  400nm)	  
	  
	  
	   In	  the	  treatment	  of	  VSMCs	  with	  20	  μM	  17-­‐β	  estradiol	  (Figure	  7)	  we	  had	  n=16	  
for	  each	  treatment	  and	  control.	  The	  findings	  of	  the	  experiment	  showed	  statistical	  
significance	  with	  p<0.05.	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Figure	  8:	  Percentage	  of	  viable	  cells	  after	  treatment	  with	  20	  μM	  17-­‐β	  estradiol	  at	  differing	  time	  points	  
when	  compared	  to	  control	  	  
	  
	   The	  static	  weight	  studies	  performed	  simulated	  the	  pressure	  VSMCs	  feel	  
during	  balloon	  expansion.	  In	  both	  the	  24	  and	  72-­‐hour	  studies,	  statistically	  
significant	  differences	  were	  observed	  with	  p=0.0013	  between	  treated	  treatment	  and	  
the	  untreated	  control	  (simulation	  of	  normal	  balloon	  angioplasty)	  at	  24	  hours	  
(Figure	  8)	  and	  p=0.0001	  at	  72	  hours	  (Figure	  9).	  The	  comparison	  between	  treatment	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statistical	  significance	  at	  24	  and	  72	  hours	  (p=0.0003	  and	  p=0.01	  respectively).
	  	  
Figure	  9:	  MTT	  assay	  results	  for	  cell	  viability	  after	  24	  hours	  (p<0.05	  for	  both	  Treated	  compared	  to	  
Control	  (Untreated)	  and	  Treated	  compared	  to	  Indenter	  Control)	  
	  
	  
Figure	  10:	  MTT	  assay	  results	  for	  cell	  viability	  after	  72	  hours	  (p<0.05	  for	  both	  Treated	  compared	  to	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   In	  the	  TUNEL	  Apoptotic	  assays,	  over	  1000	  cells	  in	  the	  treatment	  were	  
compared	  to	  control	  groups	  to	  determine	  any	  statistically	  significant	  difference	  in	  
the	  amount	  of	  apoptosis	  at	  24	  and	  72	  hours	  (Figure	  10	  and	  11	  respectively).	  Neither	  
were	  proven	  significantly	  different	  with	  p=0.1814	  in	  the	  24-­‐hour	  study	  and	  
p=0.2125	  in	  the	  72-­‐hour	  study.	  Cell	  count	  analysis	  was	  performed	  in	  ImageJ	  with	  
the	  images	  from	  the	  fluorescence	  microscope	  (Figure	  12).	  	  
	  
Figure	  11:	  The	  percentage	  of	  cells	  that	  were	  apoptotic	  compared	  to	  total	  cells	  in	  treated	  simulation	  




Figure	  12:	  The	  percentage	  of	  cells	  that	  were	  apoptotic	  compared	  to	  total	  cells	  in	  treated	  simulation	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Figure	  13:	  Fluorescent	  microscopy	  images	  showing	  DAPI	  stained	  nuclei	  (top	  left),	  GFP	  tagged	  
apoptotic	  cells	  (top	  right),	  and	  an	  overlay	  of	  the	  two.	  
	  
	   The	  hypertrophic	  studies	  were	  completed	  with	  looking	  at	  more	  than	  125	  
different	  cells	  in	  each	  group	  and	  examining	  their	  area.	  The	  analysis	  showed	  no	  
statistical	  difference	  with	  p=0.0823	  for	  the	  24-­‐hour	  study	  (Figure	  13)	  and	  p=0.0806	  
for	  the	  72-­‐hour	  study	  (Figure	  14).	  	  The	  treated	  and	  untreated	  group	  did	  both	  show	  
consistency	  in	  the	  average	  cell	  area	  between	  the	  24	  and	  72-­‐hour	  studies.	  The	  study	  
of	  major	  and	  minor	  axes	  (Figure	  15	  and	  16)	  were	  used	  to	  determine	  if	  VSMCs	  were	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in	  contractile	  or	  synthetic	  phenotype,	  with	  aspect	  ratios	  (length	  of	  major	  axis/length	  
of	  minor	  axis)	  closer	  to	  1	  indicating	  more	  synthetic	  phenotype	  cells.	  	  
	  
Figure	  14:	  Study	  to	  compare	  average	  cell	  area	  and	  look	  for	  cell	  hypertrophy	  between	  treated	  
simulation	  (treatment)	  (n=151)	  and	  untreated	  simulation	  (control)	  (n=188)	  
	  
	  
Figure	  15:	  Study	  to	  compare	  average	  cell	  area	  and	  look	  for	  cell	  hypertrophy	  between	  treated	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Figure	  16:	  Ratio	  of	  major	  and	  minor	  cell	  axes	  
	  
	  
Figure	  17:	  Ratio	  of	  major	  and	  minor	  cell	  axes	  (average	  and	  SD	  or	  standard	  error)???	  
	  
	   Images	  from	  the	  fluorescence	  microscope	  (Figure	  17)	  were	  analyzed	  in	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Figure	  18:	  Fluorescence	  microscopy	  photo	  of	  VSMCs	  with	  actin	  filaments	  tagged	  with	  Phalloidin	  and	  
nuclei	  stained	  with	  DAPI.	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Figure	  19:	  Fluorescence	  microscopy	  pictures	  of	  different	  coating	  techniques.	  
	   The	  representation	  of	  different	  coating	  solvents	  and	  solutions	  (Figure	  18)	  
was	  done	  with	  light	  microscopy	  (left	  column),	  fluorescent	  microscopy	  (middle	  
column)	  and	  overlays	  (right	  column)	  to	  examine	  homogenous	  estrogen	  coating	  of	  
the	  PET	  sheets.	  The	  figure	  shows	  estrogen	  and	  iopromide	  dissolved	  in	  100%	  
ethanol	  (top	  row)	  and	  acetone	  (2nd	  row)	  as	  well	  as,	  estrogen	  alone	  dissolved	  in	  
100%	  ethanol	  (3rd	  row)	  and	  an	  uncoated	  sheet	  (bottom	  row).	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CHAPTER	  IV	  
Discussion:	  
	   	  
	   Both	  Western	  Blot	  and	  Immunostaining	  show	  the	  presence	  of	  α-­‐actin	  and	  
myosin	  heavy	  chain.	  Their	  presence	  confirms	  that	  the	  cells	  are	  VSMCs.	  
	   	  MTT	  assay	  measures	  the	  amount	  that	  is	  converted	  to	  formazan	  crystals	  by	  
living	  cells	  [26].	  This	  conversion	  occurs	  within	  the	  cell’s	  mitochondria,	  thus	  giving	  
us	  a	  measure	  of	  the	  cell	  viability	  [26].	  	  
	   In	  24-­‐hour	  study	  of	  the	  antiproliferative	  effects	  of	  17-­‐β	  estradiol	  on	  VSMCs	  
we	  can	  see	  that	  at	  5	  minutes	  in	  20	  μM	  17-­‐β	  estradiol	  there	  are	  already	  almost	  a	  20%	  
decrease	  in	  the	  number	  of	  cells	  (81.77%	  viability).	  This	  number	  also	  does	  not	  lower	  
significantly	  at	  15	  or	  even	  30	  minutes	  (76.02%	  and	  77.4%	  respectively)	  showing	  
that	  the	  17-­‐β	  estradiol	  has	  an	  antiproliferative	  effect	  on	  its	  own	  and	  in	  a	  short	  
period	  of	  time.	  This	  data	  has	  been	  shown	  to	  be	  statistically	  significant	  (p<0.05)	  with	  
a	  sample	  size	  of	  n=16	  used	  for	  each	  data	  point.	  
	   	  
	   The	  results	  of	  our	  24	  and	  72-­‐hour	  studies	  (shown	  in	  figures	  8	  and	  9	  
respectively)	  indicate	  that	  both	  the	  cells	  that	  were	  exposed	  to	  a	  simulation	  of	  
treated	  balloon	  expansion	  and	  the	  cells	  exposed	  to	  a	  simulation	  of	  untreated	  balloon	  
expansion	  incurred	  cell	  detachment	  leading	  to	  a	  lower	  number	  of	  viable	  cells	  when	  
compared	  to	  the	  indenter	  control	  group	  (cells	  placed	  only	  under	  the	  weight	  of	  the	  
indenter).	  However,	  72	  hours	  after	  balloon	  expansion	  simulation	  was	  completed,	  
the	  untreated	  treatment	  group	  had	  proliferated	  to	  a	  much	  higher	  of	  number	  viable	  
cells	  when	  compared	  to	  the	  control,	  while	  the	  cells	  that	  had	  undergone	  simulation	  of	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an	  estrogen-­‐Iopromide	  treated	  balloon	  expansion,	  was	  still	  less	  than	  the	  indenter	  
control.	  The	  marked	  increase	  in	  the	  amount	  of	  cells	  in	  the	  untreated	  group	  show	  
that	  without	  antiproliferative	  drugs,	  VSMCs	  respond	  to	  the	  injury	  incurred	  by	  
balloon	  expansion	  with	  an	  increased	  rate	  of	  cell	  proliferation.	  In	  vivo	  this	  quick	  
proliferation	  of	  cells	  would	  lead	  to	  restenosis	  of	  the	  vessel	  through	  neointimal	  
hyperplasia.	  While	  this	  study	  does	  not	  show	  the	  vascular	  recoil	  response	  that	  is	  
normally	  associated	  with	  balloon	  angioplasty	  and	  causes	  early	  partial	  reocclusion	  of	  
the	  vessel,	  it	  does	  give	  a	  clear	  indication	  that	  balloons	  coated	  with	  anti-­‐proliferative	  
drug	  will	  help	  stem	  neointimal	  hyperplasia	  	  
	   The	  DeadEnd™	  Fluorometric	  TUNEL	  assay	  detects	  and	  quantifies	  apoptotic	  
cells	  within	  a	  cell	  population	  by	  measuring	  the	  fragmented	  DNA	  of	  apoptotic	  cells	  
[27].	  This	  assay	  uses	  rTdT	  to	  label	  fragmented	  DNA	  with	  fluorescein-­‐12-­‐dUTP	  at	  the	  
3’-­‐OH	  ends.	  The	  labeled	  DNA	  can	  then	  be	  observed	  using	  fluorescence	  microscopy	  
and	  then	  the	  number	  of	  apoptotic	  cells	  can	  be	  compared	  to	  the	  total	  number	  of	  cells	  
(non	  apoptotic	  cells	  tagged	  with	  DAPI).	  	  The	  apoptotic	  assay	  shows	  no	  statistical	  
difference	  in	  the	  percentage	  of	  apoptotic	  cells	  when	  comparing	  treated	  balloon	  
expansion	  simulation	  to	  untreated	  at	  24	  and	  72	  hours	  (p-­‐values=	  0.1814	  and	  0.2125	  
respectively).	  This	  tells	  us	  that	  our	  estrogen-­‐Iopromide	  treatment	  causes	  no	  more	  
apoptosis	  than	  untreated	  balloon	  angioplasty.	  	  
	  	   For	  hypertrophy	  study	  we	  were	  looking	  to	  ensure	  that	  the	  estrogen-­‐
Iopromide	  treatment	  did	  not	  cause	  any	  increase	  cell	  growth	  as	  compared	  to	  
untreated	  balloon	  angioplasty.	  The	  Phalloidin	  binds	  to	  the	  polymerized	  actin	  in	  the	  
cells	  that	  helps	  determine	  area	  of	  the	  cell	  and	  major	  and	  minor	  axes.	  Using	  12	  
pictures from each sample group, the cells were measured using Image J (NIH) to 
find the cell area along with the lengths of the major and minor axes. The results 
displayed in figures 13 and 14 showed that there was no statistical difference in the 
area of the cells at 24 hours (p=0.0823) or at 72 hours (p=0.0806). VSMCs that have 
transitioned from the contractile phenotype to the synthetic phenotype are 
normally more rounded and have an aspect ratio closer to 1. The aspect ratio 
comparison shows that the cells that were in the treated group at 24 hours had an 
aspect ratio closer to one, while untreated group had a higher aspect ratio hence 
showing more contractility than treated group. However, after 72 hours the treated 
group had a higher aspect ratio that was closer to untreated control group.  
 The fluorescence microscopy pictures of our three coating techniques 
showed that the 17-β estradiol-Iopromide mixture dissolved in 100% ethanol gave 
the most uniform distribution of drug on the PET sheets. The estrogen auto-




Conclusions and Recommendations: 
 
  The use of antiproliferative agents to aid in interventional cardiology 
has been well documented to solve many of the problems associated with balloon 
angioplasty in the coronary and peripheral arteries. While uncoated have not been 
as successful at keeping a vessel open, the addition of antiproliferative agents can 
stem the neointimal hyperplasia that causes reocclusion. Drug-coated balloons as of 
yet have not been able to solve the vascular recoil after balloon deflation, and as 
such are not yet the best option for most cases to use alone. As of now, drug-coated 
balloons are shown to be effective to fight in-stent restenosis, deployment of bare 
metal stents and to open the lumen of areas where it is dangerous and/or difficult to 
place stents for longer periods than uncoated balloons. The estrogen-Iopromide 
coating we developed has shown signs that it can compete with alternatives such as 
Paclitaxel and other drugs used on balloon on the market in Europe and undergoing 
FDA testing in the United States. These studies have shown that our coating is 
effective at stemming VSMC proliferation at low doses and short release times 
without cause anymore apoptosis or cell hypertrophy than uncoated balloons. 
 
 For further exploration of the effects on estrogen alone, studies will be 
carried out with more time after treatment before analysis. One and two week 
studies will help to show how long the antiproliferative effects of estrogen are felt. 
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 To test a DCB and determine how much drug is lost and if a sheath should be 
used to protect a DCB we designed a novel dynamic flow model to simulate the 
pathway an interventional cardiologist would traverse when deploying a DCB in the 
superficial femoral artery. 
 The superficial femoral artery is one of the top areas that interventional 
cardiologists and vascular surgeons are looking at the use of drug-coated balloons 
[9]. The SFA is an area where atherosclerosis occurs frequently and the high 
stresses placed on the artery make it difficult to stent without complications [9]. For 
our dynamic flow model design we will have all the arteries that are involved in 
balloon deployment in the SFA. The balloon will be inserted in the iliac artery and be 
guided up to where the thoracic aorta splits into the iliac arteries. From there, the 
balloon traverses the opposite iliac artery and then continues to the femoral 
bifurcation. It will then enter the superficial femoral artery. To ensure a proper 
simulation of the rate of blood flow in these areas we have used Bernoulli’s energy 
balance equation as well as taking into account the conservation of mass. We have 
sized all of our tubing to mimic that of the vessels used. These sizes include inner 
diameters: thoracic aorta at 10mm, common iliac artery at 8mm, and the superficial 
femoral artery at 6mm.  
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Figure 20: Picture of the dynamic flow simulator 
 
 For our experiments, we will use a Cole-Parmer peristaltic pump (Cole-
Parmer, IL, USA) to circulate the blood analog. We will use this device to achieve the 
400-600 mL/min flow rate normally seen in the SFA. All of the artery analogs in the 
model will empty into a catch pan where the pump will recirculate it. This will 
ensure that any drug lost in transit to the deployment site will be captured in the 
cycle and we can then analyze the amount lost through HPLC. The tubing we chose 
to mimic the iliac arteries and SFA are made of clear PVC. When the tubing is left in 
acetone it will harden and shrink. After initial testing on smooth untreated tubing 
(simulating a healthy person) to ensure our experiment works, we will begin to try 
scenarios that simulate stenosed arteries. This will assure us that the DCB will be 
able to perform in the environment they will be subjected to in patients. 
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 Based on the results gathered from the dynamic flow model we will be able 
to determine if the coating techniques used are the correct ones, how much drug is 
lost with different coating techniques, the coatings stability in an environment 
similar to blood, and if a sheath is necessary to prevent the majority of the drug 
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